Kidney Transplant Market Size & Growth Forecast 2026–2035, By Segments (Preservation Method, Transplant Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Kidney Transplant Market size stood at USD 9.68 Billion in 2025 and is predicted to grow at a 7% CAGR from 2026 to 2035, surpassing USD 19.04 Billion by 2035. The industry revenue for 2026 is estimated at USD 10.27 billion.

• Base Year Value (2025): USD 9.68 Billion
• CAGR (2026-2035): 7%
• Forecast Year Value (2035): USD 19.04 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Kidney Transplant Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America’s leadership is supported by established transplant infrastructure, specialized centers, and mature systems for organ procurement and patient care.
  • Asia Pacific is projected to grow at a 7.91% CAGR, supported by improving healthcare capacity and broader access to advanced transplant procedures.

• Segment Momentum:

  • Static Cold Storage leads with a 47.17% share due to clinical familiarity, simple handling, and established integration into existing transplant workflows across hospitals and centers.
  • Living donor transplants are growing as they enable planned procedures and reduce waiting uncertainty, improving access to timely transplantation compared with deceased donor pathways.

• Market Expansion Drivers:

  • Rising prevalence of chronic kidney disease and ESRD increasing demand for transplant procedures.
  • Advancements in immunosuppressive therapies and surgical techniques improving transplant success rates.
  • Expanding kidney paired exchange and living donor programs improving transplant accessibility.

• Leading Market Participants:

  Top players in the kidney transplant market include TransMedics Group, Inc. (United States), XVIVO Perfusion AB (Sweden), OrganOx Limited (United Kingdom), Paragonix Technologies, Inc. (United States), Organ Recovery Systems, Inc. (United States), Bridge to Life Ltd. (United States), Waters Medical Systems LLC (United States), Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 9.68 Billion
  • Projected Market Size: USD 19.04 Billion by 2035
  • Growth Forecasts: 7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Static Cold Storage (SCS) (Preservation Method) | Deceased Donor Transplants (Transplant Type)
  • Emerging Opportunity Segment: Normothermic Machine Perfusion (NMP) (Preservation Method) | Living Donor Transplants (Transplant Type)

Market Growth Drivers and Industry Trends

Rising prevalence of chronic kidney disease and ESRD increasing demand for transplant procedures

The growing burden of chronic kidney disease and end-stage renal disease is directly enlarging the pool of patients evaluated for renal replacement options, with transplant increasingly prioritized over long-term dialysis because of better clinical outcomes and lower lifetime treatment intensity. In the kidney transplant market, This transitions hospital resources, referral patterns, and waitlist management toward earlier transplant assessment, while also increasing demand for donor matching services, organ preservation, and post-transplant care infrastructure. As more patients progress to ESRD, providers and payers face stronger pressure to move eligible candidates into transplant pathways, reinforcing market demand for the full transplant ecosystem rather than only procedural volume.

Advancements in immunosuppressive therapies and surgical techniques improving transplant success rates

Improvements in immunosuppressive regimens and transplant surgery are changing physician and patient decision-making by reducing the perceived risk of graft rejection, perioperative complications, and poor long-term outcomes. In the kidney transplant market, stronger graft survival and more predictable recovery support broader clinical confidence in transplant as a viable treatment pathway, including for more complex recipients who may previously have been considered borderline candidates. This is driving demand for newer drug protocols, specialized transplant centers, and long-term monitoring services, while also strengthening market development through better utilization of available donor organs.

Expanding kidney paired exchange and living donor programs improving transplant accessibility

The expansion of kidney paired exchange networks and living donor programs is addressing one of the most practical constraints in transplantation: incompatibility between willing donors and intended recipients. By improving match opportunities and shortening the path to surgery for eligible patients, these programs increase procedural throughput and reduce dependence on deceased donor availability. For the kidney transplant market, that translates into higher transplant center activity, greater coordination needs across registries and care teams, and increasing market penetration of services tied to donor evaluation, matching logistics, and perioperative management.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of chronic kidney disease and ESRD increasing demand for transplant procedures	2.00%	High	North America, Europe, Asia Pacific	High	Near Term
Advancements in immunosuppressive therapies and surgical techniques improving transplant success rates	1.80%	High	North America, Europe	High	Mid Term
Expanding kidney paired exchange and living donor programs improving transplant accessibility	1.50%	High	North America, Middle East & Africa	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the kidney transplant market, supported by its well-established transplant infrastructure, broad concentration of specialized transplant centers, and mature organ procurement and allocation systems. These conditions help move patients more efficiently from diagnosis and waitlist management to surgery and post-transplant monitoring, which sustains procedural volumes and ongoing use of transplant-related therapies and services. The region’s leadership is also aided by strong clinical capabilities in donor matching, immunosuppressive treatment management, and long-term follow-up care, all of which are central to how this market functions in practice.

Asia Pacific is projected to expand at a 7.91% CAGR over the forecast period, with growth in the kidney transplant market being fueled by improving access to advanced transplant procedures and the gradual expansion of healthcare capacity across major countries in the region. Adoption is accelerating as more hospitals build transplant capabilities, patient access to specialized nephrology and surgical care improves, and awareness of transplantation as a treatment pathway increases. The region’s growth trajectory is also being supported by the practical scaling of transplant ecosystems, including better coordination across diagnosis, referral, surgery, and post-operative care.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Nascent	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Supportive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Weak	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Advanced Transplant Innovation

The U.S. continues to prioritize expanded transplant capacity through advanced surgical techniques, organ preservation technologies, and digital coordination across transplant centers. Ongoing investment in donor management and post-transplant care supports broader adoption of innovative kidney transplant solutions.

Japan

Precision Patient Management

Japan focuses on improving long-term transplant success through personalized patient monitoring and careful immunosuppressive management. Growing clinical interest in preservation technologies and minimally invasive procedures supports continued development of the kidney transplant market.

South Korea

Digital Transplant Coordination

South Korea integrates digital healthcare platforms with transplant services to streamline patient evaluation and post-operative monitoring. The country's emphasis on hospital innovation encourages adoption of advanced preservation technologies and specialized transplant care solutions.

Germany

Clinical Quality Integration

Germany emphasizes standardized transplant protocols and multidisciplinary care to improve kidney transplant outcomes. The country supports demand for advanced immunosuppressive therapies, organ preservation systems, and hospital-based technologies that strengthen clinical efficiency.

France

Coordinated Care Networks

France strengthens kidney transplant services through coordinated hospital networks and structured patient follow-up programs. The market benefits from continued focus on organ preservation, transplant logistics, and technologies that improve long-term graft management.

Italy

Specialized Surgical Expansion

Italy continues to enhance kidney transplant capabilities by expanding specialized surgical expertise and improving coordination between transplant centers. Demand remains focused on preservation technologies, immunosuppressive therapies, and solutions that optimize patient recovery pathways.

Segment Leadership and Growth Trends

  Preservation Method Segment Analysis: Static Cold Storage (SCS) (Largest Segment) vs Normothermic Machine Perfusion (NMP) (Fastest-Growing Segment)

Static Cold Storage (SCS) held the leading position in the kidney transplant market in 2025, accounting for a 47.17% share. Its continued leadership is rooted in entrenched clinical use, broad familiarity across transplant centers, and the operational simplicity it offers during organ handling and transport. In the kidney transplant market, SCS remains the default preservation method because it fits existing workflows without requiring major changes in infrastructure or handling protocols, which helps sustain its dominant share.

Normothermic Machine Perfusion (NMP) is emerging as the fastest-growing preservation approach in the kidney transplant market as transplant programs increasingly seek methods that support more active organ preservation and assessment before implantation. Its momentum is being driven by the practical need to improve utilization of available donor kidneys, especially when centers are working under pressure to optimize organ viability and decision-making. Compared with conventional storage approaches, NMP is gaining traction because it aligns with the growing emphasis on expanding transplant eligibility and supporting more informed organ acceptance practices.

Transplant Type Segment Analysis: Deceased Donor Transplants (Largest Segment) vs Living Donor Transplants (Fastest-Growing Segment)

Deceased Donor Transplants represented the largest segment of the kidney transplant market in 2025, with a 70.46% share. This leadership is primarily sustained by the established reliance of transplant systems on deceased donor organ availability to serve a broader patient pool. Across the kidney transplant market, deceased donor pathways remain central to transplant activity because they are embedded in procurement networks, allocation systems, and hospital workflows that support high procedural volumes relative to other transplant types.

Living Donor Transplants are the fastest-growing segment in the kidney transplant market, aided by increasing focus on improving transplant timing and reducing dependence on deceased donor waiting pathways. Growth in this segment reflects the practical advantage of being able to plan procedures more efficiently and move eligible patients to transplant without the same level of uncertainty tied to deceased donor availability. Relative to alternatives, living donor transplants are gaining momentum because they offer a more controlled route to transplantation within systems seeking to address access constraints.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Preservation Method	Static Cold Storage (SCS), Hypothermic Machine Perfusion (HMP), Normothermic Machine Perfusion (NMP)	Static Cold Storage (SCS)	Normothermic Machine Perfusion (NMP)
Transplant Type	Living Donor Transplants, Deceased Donor Transplants, Donation After Brain Death (DBD), Donation After Circulatory Death (DCD)	Deceased Donor Transplants	Living Donor Transplants

Competitive Landscape and Market Positioning

Major players in the kidney transplant market:

1. TransMedics Group Inc. (United States)

2. XVIVO Perfusion AB (Sweden)

3. OrganOx Limited (United Kingdom)

4. Paragonix Technologies Inc. (United States)

5. Organ Recovery Systems Inc. (United States)

6. Bridge to Life Ltd. (United States)

7. Waters Medical Systems LLC (United States)

8. Sanofi S.A. (France)

9. Novartis AG (Switzerland)

10. Pfizer Inc. (United States)

The kidney transplant market is evolving through advancements in immunosuppressive therapies, transplant diagnostics, and personalized patient monitoring solutions. Collaborative clinical research efforts and innovation in organ compatibility assessment technologies are supporting improved transplant success rates and long-term patient outcomes. Rising focus on precision medicine and post-transplant care optimization is also strengthening development activity within the kidney transplant market.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Market Concentration	High	Dominated by specialized medical centers and pharma firms (e.g., Novartis, Astellas).
M&A Activity / Consolidation Trend	Low	Limited M&A due to niche market and strict regulatory oversight in transplant services.
Degree of Product Differentiation	Medium	Variations in immunosuppressants and surgical tech, but standardized procedures.
Competitive Advantage Sustainability	Durable	Chronic kidney disease prevalence and regulatory barriers ensure stable demand.
Innovation Intensity	Medium	Advances in immunosuppressants and organ preservation; not highly transformative.
Customer Loyalty / Stickiness	Strong	High trust in specialized centers and long-term care lock in patients.
Vertical Integration Level	High	Centers control surgery, drugs, and follow-up care for integrated treatment.

Industry Development/News

Company Name	Date	Key Development
eGenesis	Sep-24	eGenesis secured USD 191 million in Series D funding to accelerate the clinical development of EGEN-2784, its lead porcine-derived kidney transplant candidate. This financing, led by Lux Capital, provides the capital necessary for first-in-human trials and the scaling of production infrastructure, marking a critical step in the commercialization of xenotransplantation technology for end-stage renal disease patients.
United Therapeutics Corporation	Nov-24	United Therapeutics successfully completed the first human transplant of a genetically modified porcine kidney. This achievement marks a significant advancement in xenotransplantation, demonstrating technical feasibility for addressing the chronic shortage of human donor organs and establishing a foundation for potential future clinical adoption of porcine-derived kidney therapies.
SERB Pharma	May-26	SERB Pharma acquired the rights to Idefirix, a desensitization therapy designed for highly sensitized patients awaiting kidney transplantation. This acquisition strategically enhances the company’s transplant portfolio by addressing critical immunological barriers to transplantation, thereby expanding the potential pool of compatible donor-recipient matches and increasing procedural access for previously difficult-to-treat patient populations.
Hoag	Mar-26	Hoag initiated plans to launch a new organ transplant center in Orange County, incorporating dedicated liver and kidney transplant services. This facility expansion represents a strategic move to increase regional transplant capacity and operational throughput, pending final regulatory approvals to commence clinical procedures.
Hansa Biopharma	Sep-25	Hansa Biopharma reported positive Phase III clinical results for its imlifidase therapy. The data supports the regulatory pathway for U.S. market entry, positioning the drug to potentially address unmet needs in the kidney transplant sector by enabling transplantation in highly sensitized patients who otherwise remain on long-term dialysis.
Montefiore Einstein	Aug-25	Montefiore Einstein expanded its surgical capabilities through the adoption of robotic-assisted kidney transplantation. This technology integration aims to improve surgical outcomes and broaden transplant eligibility, particularly for complex patient profiles who may face elevated risks under traditional open-surgery protocols, thereby increasing the overall efficiency and reach of the institution's transplant program.
Prisma Health	Sep-24	Prisma Health significantly scaled its regional transplant operations, reporting a substantial increase in kidney transplant volumes following the launch of its dedicated Transplant Center. This growth reflects a successful expansion of regional service capacity and a hardening of infrastructure to meet local demand for complex transplant surgical care.
Thermo Fisher Scientific	May-24	Thermo Fisher Scientific commercialized a non-invasive, urine-based assay specifically for kidney transplant recipients. This diagnostic innovation facilitates enhanced post-transplant health monitoring and patient management, representing a strategic shift toward utilizing molecular diagnostics to improve long-term graft survival and operational efficiency in transplant care programs.
Carilion Clinic	Feb-24	Carilion Clinic announced a strategic initiative to establish an adult kidney transplant program at Carilion Roanoke Memorial Hospital. This proposed expansion is designed to extend specialized transplant services to a new regional catchment area, pending regulatory approval, effectively increasing the geographic availability and accessibility of end-stage renal disease treatment options.